Aleix Prat

68PUBLICATIONS
365CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersModels of care and place of birthGene expression (incl. microarray and other genome-wide approaches)Environmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (68)

|Oct 30, 2026
5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.

|Oct 08, 2026
Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.

|Apr 08, 2026
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.

Alexios Matikas, Evangelos Tzoras, Michail Sarafidis

|Feb 16, 2026
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO).

Tomás Pascual, Maria Vidal, Juan M Cejalvo

|Jan 22, 2026
Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Benedetta Conte, Fara Brasó-Maristany, Tomás Pascual

|Dec 03, 2025
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial.

Eva Ciruelos, Tomás Pascual, Guillermo Villacampa

Pageof 12

Frequent Collaborators

23 joint publications

Tomas Pascual

15 joint publications

Fara Brasó-Maristany

12 joint publications

Mafalda Oliveira

12 joint publications

Maria Vidal Losada